Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosposertib alone and with pembrolizumab in advanced solid tumors
NCT05204862Phase 2Recruiting
- Sponsor
- TiumBio Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tosposertib in solid tumor (advanced stage) (5 arms), sponsored by TiumBio Co., Ltd. Primary endpoints: Maximum Tolerated Dose at Cycle 2 and Overall Response Rate at 24 weeks. Started Dec 2021; status: recruiting.
02
Drugs
tosposertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05204862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204862.